Clarity Pharmaceuticals (ASX:CU6) has secured a significant manufacturing supply agreement with US-based Theragenics for copper-64, crucial for its lead diagnostic candidate, 64Cu SAR bisPSMA. This partnership, centered on Theragenics’ advanced facility in Atlanta, enables large-scale production of copper-64 necessary for cancer imaging. The agreement signifies Clarity’s transition from late-stage clinical development towards commercial readiness, contingent on successful Phase 3 trials and US regulatory approval. Additionally, it fosters a more scalable and economically viable model for radiodiagnostics, potentially enhancing patient access and operational efficiency for healthcare providers.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://biotechdispatch.com.au/news/clarity-advances-us-manufacturing-strategy-with-major-copper-64-supply-agreement
